SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

A. Luger, Thomas; van Leent, E.J.M.; Graeber, Michael; Hedgecock, S.; Thurston, Mark; Kandra, Albert; Berth‐Jones, J.; Roar Bjerke, Jens; Christophers, Enno; Knop, J.; C. Knulst, André; Morren, Marie; Morris, Adrian; Reitamo, Sakari; Roed‐Petersen, J; Schoepf, Erwin; Thestrup-Pedersen, K.; van der Valk, P.G.M.; Bos, J.D.

doi:10.1046/j.1365-2133.2001.04134.x

Public

SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

Published in British Journal of Dermatology • Apr 1, 2001

Authors:

Thomas A. Luger

E.J.M. van Leent

Michael Graeber

Abstract

BACKGROUND: SDZ ASM 981 is a selective inhibitor of the production of pro-inflammatory cytokines from T cells and mast cells in vitro. It is the first ascomycin macrolactam derivative under development for the treatment of inflammatory skin diseases. OBJECTIVES: This study was designed to determine ...

Subject

Atopic dermatitis

Medicine

Dermatology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!